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Subacute Oral Toxicity Investigation of Selenium Nanoparticles and 
Selenite in Rats  
 
Selenium (Se) nanoparticles have been proposed as food supplements. However, 
the particle formulation may exert unexpected toxicity. The aim was therefore to 
compare toxicity of low doses of Se nanoparticles and the dissolved, ionised Se 
species selenite. Female rats were dosed orally for 28 days with either: 0.05, 0.5 
or 4 mg Se/kg body weight (bw)/day as 20 nm Se nanoparticles or 0.05 or 0.5 mg 
Se/kg bw/day as sodium selenite. Male rats were dosed 4 mg Se/kg bw/day as Se 
nanoparticles. Body weight and clinical appearance were recorded throughout the 
experiment. At necropsy, blood samples were taken for haematological and 
clinical chemistry analyses; organ weights were recorded. At the high dose of Se 
nanoparticles, overt toxicity occurred and the female animals had to be 
euthanised prematurely, whereas the male animals were reduced in dose. At all 
doses of Se nanoparticles and at 0.5 mg Se/kg bw/day as selenite, a lower body 
weight gain as compared to vehicle occurred. Relative liver weight was increased 
for both Se formulations at 0.5 mg Se/kg bw/day. Creatinine clearance and 
urinary pH were affected in some Se dosed groups. There were no effects among 
dosed groups on brain neurotransmitters or on haematological parameters 
compared with controls. There were no histological changes in the livers of 
animals exposed to Se nanoparticles or to selenite. Based on effects on body 
weight and liver weight, selenium nanoparticles and ionic Se exerted similar 
toxicity. This suggests that a nanoparticle-specific toxicity of Se did not occur. 




Selenium (Se) is an essential element, necessary for proper cellular function (Levander 
1982, Bulteau and Chavatte 2015). Se has been suggested to be effective in cancer 
prevention among individuals with low Se status (Vinceti et al. 2014). Se is a constituent 
of most food supplements with recommended daily doses of typically 50-100 µg. The 
tolerable upper intake level is 300 µg/day (SCF 2006). Signs of Se toxicity are e.g. 
gastrointestinal disorders, irritability, fatigue, hair loss, nail brittleness, dizziness, nausea, 
concentration difficulties, pulmonary oedema, liver cirrhosis and ultimately mortality 
(Nelson et al. 1943, Sioris et al. 1980, Köppel et al. 1986, Matoba et al. 1986, Hawkes et 
al. 1992, Hunsaker et al. 2005, See et al. 2006, Spiller and Pfiefer 2007, Sutter et al. 2008, 
MacFarquhar et al. 2010, Müller and Desel 2010). The window between intake of Se 
from food and food supplements and the tolerable upper intake level is narrow. Se 
nanoparticles (SeNP) are considered to provide a depot formulation of Se through gradual 
release of dissolved Se from the particle surface. A gradual release formulation has been 
proposed to be desirable for safer food supplements (Kojouri, Jahanabadi, et al. 2012, 
Skalickova et al. 2017). Regarding toxicity, the hypothesis we aimed at investigating was 
whether SeNP have effects analogous to the molecular selenium species used in food 
supplements or whether they exert any particle specific toxicity. Particles may disrupt 
biological structures due to their physical form and catalytic reactions may take place on 
the particle surface. Thus, it is relevant to assess whether particle specific toxicity occurs 
for Se, and whether toxicity occurs at higher or lower doses as compared to more 
traditional ionic Se preparations. This has been addressed in a range of studies. SeNP (20-
60 nm in diameter) have been shown to have an acute toxicity seven fold lower than that 
for selenite in mice based on mortality (Zhang et al. 2001). Furthermore, Zhang et al. 
found that oral doses of 6 mg Se/kg bw/day as selenite or as SeNP (20-60 nm) for 12 days 
to mice suppressed weight gain and induced changes in liver enzymes, with selenite 
exerting the greatest effect (Zhang et al. 2005). Also, at 2 and 4 mg Se/kg bw/day, selenite 
suppressed growth of mice to a greater extent than SeNP (Zhang et al. 2005). Benko et 
al. found selenite and SeNP (100-500 nm in diameter) to be almost equally toxic 
considering effects on white blood cell counts after administration of 0.004, 0.04 and 0.4 
mg Se/kg bw/day for 14 days (Benko et al. 2012). In a 13-week rat feeding study, only a 
slight difference in toxicity between the same two Se preparations was observed based on 
haematology and organ weight; administered doses were 0.1, 0.2, 0.3 and 0.4 mg Se/kg 
bw/day as SeNP (20-60 nm in diameter) or selenite and the no observed adverse effect 
level (NOAEL) was 0.1 mg/kg bw for selenite as compared to NOAEL of 0.2 mg/kg bw 
for SeNP (Jia et al. 2005). Similar toxicity of SeNP and selenite was demonstrated in 
sheep; an oral dose of 1 mg/kg Se bw/day of SeNPs (smaller than 220 nm) or selenite 
administered for 10 days resulted in similar effects on serum iron, transferrin expression 
and increased neutrophil chemotactic activities (Kojouri, Jahanabadi, et al. 2012, Kojouri, 
Sadeghian, et al. 2012).  
           To provide further knowledge on the toxicity of SeNP compared to a dissolved, 
ionised Se species, we used SeNP 20 nm in diameter and Se in the form of selenite. SeNP 
was administered at doses ranging from 0.05 (equal to 1.5 fold to the human tolerable 
upper intake level, when converted by difference in body surface area according to 
(Reagan-Shaw et al. 2008)(low-dose)) via 0.5 (supra-nutritional dose (mid-dose)) to 4 
(high-dose) mg Se/kg bw/day. Selenite was administered to rats at equal low- and mid-
doses. The compounds were administered by oral gavage to rats for 28 days. To address 
general toxicity, standard toxicity parameters were measured. Se toxicity in humans has 
been reported to include such effects as paraesthesia, memory loss and difficulties of 
concentration  (Clark et al. 1996, Sutter et al. 2008, Aldosary et al. 2012). In order to 
address whether neurotoxic changes occurred, brain neurotransmitters were measured. 
Materials and Methods  
SeNP synthesis and characterisation 
SeNP were synthesised using a method developed by Zhang et al. (Zhang et al. 2001) and 
the synthesis was based on the reaction of selenite and glutathione in the presence of 
bovine serum albumin (BSA). The Se in the NPs had an oxidation state of 0. The SeNP 
were characterised with regard to their physico-chemical characteristics before and after 
the animal experiment. This included size distribution determined by dynamic light 
scattering (DLS), size and shape by transmission electron microscopy (TEM), and total 
Se concentration of the suspension by inductively coupled plasma-mass spectrometry 
before and after filtration of the suspension through 12 kDa filters (Loeschner et al. 2014). 
For DLS, undiluted, 400 mg Se/L, SeNP suspension was directly analysed. For TEM 
analysis, the suspension was diluted 10 fold with ultrapure water, The mode of the 
volume-based size distribution by DLS was at around 20  nm (Loeschner et al. 2014).  
The polydispersity index was in the range of 0.174 to 0.236 and the Z-average in the range 
of 32 to 38 nm. TEM confirmed the determined diameter and showed that the particles 
had a spherical shape (Loeschner et al. 2014). A TEM picture of the SeNP suspension 
can be seen in Figure 1. The Zeta potential of the SeNP in the undiluted suspension 
(determined by laser Doppler electrophoresis) was in the range of +10 to 20 mV (pH 4).  
 
Figure 1. TEM picture of the SeNP suspension 
 
Study design of the 28-day toxicity study  
Four weeks old Wistar rats (Wistar Hannover Galas) (Taconic M&B DK-4623, 
Lille Skensved, Denmark) with specific–pathogen-free health status (SPF), were 
weight-randomised and allowed to acclimatize for one week. The rats of the same 
sex were housed two per cage (Macrolon, Techniplats Gazzada S. ar. L., 
Buguggiate, Italy) with a 12:12-h reversed light/dark cycle with light from 7 p.m. 
to 7 a.m. The room temperature was 22±1 oC and the relative humidity 55%±5%. 
The rats were offered a standard diet (Altromin rat No.1324, Brogården, Gentofte, 
Denmark) and citric acid acidified tap water (to pH 3), to avoid microbiological 
contamination of drinking water), both ad libitum. The rats were divided into the 
following treatment groups: 1. Vehicle-BSA (4g/L) control (8 females and 6 
males), 2. SeNP low-dose (0.05 mg Se/kg bw/day) (6 females), 3. SeNP mid-dose 
(0.5 mg Se/kg bw/day) (6 females), 4. SeNP high-dose (4 mg Se/kg bw/day) (8 
females and 6 males), 5. Vehicle-H2O control (8 females), 6.  Selenite low-dose 
(0.05 mg Se/kg bw/day) (8 females) 7. Selenite mid-dose (0.5 mg Se/kg bw/day) (8 
females). The vehicle-BSA group (1) served as control group for the SeNP dosed 
animals and the vehicle-H2O group (5) served as control group for selenite dosed 
animals. The reason for having two control groups is that the SeNP had to be 
stabilised in BSA; whereas the addition of BSA was not compatible with the 
selenite. This is because the selenium atom of selenite may passively become 
incorporated into the BSA molecule in place of its natural content of sulfur in 
methionine. This would negatively affect the actual selenite concentration in 
solution before this solution was administered to the animals. At 5 weeks of age 
dose administration was done by oral gavage at a volume of 10 mL/kg bw/day. 
Selenite was administered as sodium selenite. Clinical cage-side observations were 
performed twice daily. Body weight was recorded three times per week. Feed and 
water intake was recorded at weekly intervals. The feed and water intakes were 
recorded per cage and thus per two animals. It was thus, when calculating intakes, 
estimated that the animals in each cage ate and drank equal amounts. At day 14 of 
dosing the animals were placed individually for 24 hours in metabolism cages for 
collection of urine and faeces. The urine samples were cooled by sampling on dry-
ice and subsequently stored at -80 °C until analyses. During the stay in metabolism 
cages the rats did not have access to feed. At the end of the 28-day administration 
period the rats were anaesthetised in O2/CO2 and decapitated. Blood for 
haematology and clinical chemistry was collected from the neck wound in heparin-
EDTA tubes. Plasma was prepared by centrifugation at 1000 x g at 4 ºC for 10 min. 
Following necropsy adrenals, liver, spleen, kidneys, testes, epididymis, ovaries, 
thymus, mesenteric lymph nodes, heart and brain were removed and weighed. Liver 
specimens from all animals surviving to the terminal sacrifice were fixed in 4% 
neutral buffered formaldehyde, paraffin-embedded and three micrometre-thick 
sections were stained with haematoxylin and eosin for histological examination. 
Brains from all treatment groups were processed for neurotransmitter analysis as 
described below. The Animal experiments were carried out in accordance with the 
guidelines stipulated by the National Food Institute’s Animal Welfare Committee. 
Ethical approval was given by the Danish Animal Experiments Inspectorate 
(approval number 2004/561-917). 
 
Haematology and clinical biochemistry  
White blood cell (WBC) counts, erythrocyte (RBC) counts, haemoglobin concentration 
(HGB), haematocrit (HCT), platelet (PLT) counts, mean corpuscular volume (MCV), 
mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration 
(MCHC), red cell distribution width (RDW), and mean platelet volume (MPV) were 
determined in all treatment groups using an Animal Blood Counter Vet (Horiba ABX, 
Montpellier, France). Blood smears were prepared and stained with May-Grünwald and 
Giemsa. Differential counting of lymphocytes, monocytes, neutrophil granulocytes, 
eosinophil granulocytes and basophil granulocytes was done manually by assessing 
distribution of a total of 100 cells from each animal from the following treatment groups: 
Vehicle-BSA (females and males), SeNP mid-dose, SeNP high-dose (males) and selenite 
mid-dose. Differentiation was based on morphologic criteria as described in Bailly and 
Duprat (Bailly and Duprat 1990). The following clinical biochemical plasma parameters 
were measured on a Hitachi 912 Automatic Analyzer (Boehringer Ingelheim, Ingelheim 
am Rhein, Germany) using commercially available kits purchased from Roche/Hitachi 
(IN, USA): Alanine aminotransferase (ALT) (prod. no. 10851132 216), cholesterol (kit 
prod. no. 11489232 216), total protein (prod. no.11553836 316), alkaline phosphatase 
(ALP) (prod. no. 10816388 216), glucose (prod. no. 11447513 216), urea ( prod. no. 
11489364), creatinine (prod. no. 1104084 216). Urinary glucose, bilirubin, ketones, 
specific gravity, blood, pH, total protein, urobilinogen, nitrite, and leukocytes were 
monitored by use of Multistix 10 SG (Prod. no. 2300, Siemens Health Care Diagnostics, 
NY, USA).  
Neurotransmitter analyses  
Dopamine, noradrenaline and serotonin were measured as previously described 
(Hadrup et al. 2012). A brief description is as follows, brain tissue was 
homogenised under ice-cold conditions in 0.32M sucrose, (9 mL/whole brain) using 
an UltraTurrax T25 homogeniser (IKA, Staufen, Germany). Then the homogenate 
was de-proteinised using a 1:1 volume of 0.2 M perchloric acid (HClO4) followed 
by centrifugation (20 min, 0-4 ºC, 10000 xg). For the noradrenaline and dopamine 
measurements, 3,4-dihydroxybenzylamine (Sigma, D 7012) was added as internal 
standard. Next, the samples were purified on aluminium oxide (Anton and Sayre 
1962) followed by elution with 0.2 M HClO4. For the analysis of 5-HT, N-ϖ-
methyl-5-HT (Sigma, M 1514) was added as internal standard. The 
neurotransmitters were measured using high performance liquid chromatography 
(HPLC) with electrochemical detection. The instrumentation consisted of a 
Hewlett-Packard Ti-SERIES 1100 liquid chromatograph equipped with an ESA 
MD-150 analytical column (3 mm ID   15 cm, C18, 5 mm). Separation was achieved 
with a 5% (v/v) acetonitrile modified 75 mM sodium phosphate buffer (1.7 
octenylsulfonic acid, 100 mL triethylamine/L and 25 mM EDTA; pH 3). Signals 
were detected using a dual potentiostat electrochemical detector (ESA Model 
5200A Coulochem II and ESA Model 5011 high sensitivity analytical cell with an 
E1 of 150 mV and an E2 of +220 mV; guard cell potential: +350 mV, Chelmsford, 
MA, USA). 
 
Statistical analyses  
The statistical package used was Graph Pad Prism version 4.0 by GraphPad Software 
(San Diego, CA, USA). Data were tested for normal distribution using the Kolmogorov-
Smirnov test. In case of absence of normal distribution data were transformed using the 
Log10 function before a second round of testing for normal distribution. Differences in 
mean values of normal distributed data were tested using one-way ANOVA with 
Dunnet’s post-test for vehicle-BSA control vs. SeNP groups and separately for H2O 
control vs. selenite groups. A Student’s t-test was used to test for differences of mean 
values for male BSA control vs. male SeNP high-dose. In case of absence of normal 
distribution tests the Kruskal Wallis followed by Dunn’s multiple comparisons test was 
applied. Data were expressed as mean ± SEM. P values of less than 0.05 were considered 
statistically significant.  
 
Results 
In the SeNP low-dose female group both body weight gain and body weight at the end of 
the study were lower compared to the vehicle control group. In the SeNP mid-dose female 
group only body weight gain was lower as compared to the vehicle controls (Figure 2A, 
Table 1). Regarding selenite female groups, only body weight gain in the mid-dose group 
was lower (Figure 2B, Table 1). Female rats from the SeNP high-dose group in 
comparison to the control group did not gain weight (Fig. 2A) during the first week, were 
less motorically active and local alopecia indicative of hair loss was recorded. Therefore 
the dose of SeNP was reduced from 4 to 1 mg Se/kg bw/day from day 9 to the end of the 
experiment. As males receiving SeNP high-dose started presenting the same clinical 
appearance and low weight gain (Fig 2C) the SeNP dose was reduced from 4 to 1 mg 
Se/kg bw/day from day 11. Four female rats and two male rats in the high-dose group did 
not receive SeNPs from day 11 due to the severity of the clinical signs. On day 16, all 
female rats and two male rats in the SeNP high-dose group were euthanised because of 
the disturbed clinical condition and necropsy was conducted. The remaining four male 
rats proceeded on the daily dose of 1 mg Se/kg bw as SeNP until the end of the 
experiment, and a mean dose received during the dosing period was calculated to 2.2 mg 
SeNP/kg bw/day based on 11 days with 4 mg SeNP/kg bw and 17 days with 1 mg Se/kg 
bw as SeNP. Feed and water intake were not affected in any of the groups of rats surviving 
to the scheduled termination (Table 1).  
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Figure 2. Body weight of rats administered SeNP or selenite. Rats received by gavage 
SeNP Low-dose (0.05 mg Se/kg bw/day), SeNP mid-dose (0.5 mg Se/kg bw/day) (6 
females), SeNP high-dose (4 mg Se/kg bw/day) (Panel A and B), selenite low-dose (0.05 
mg Se/kg bw/day) or selenite mid-dose (0.5 mg Se/kg bw/day) (Panel C). Body weight 
was recorded three times per week. Animals fasted during the last 24 hours of the 
experimental period, as indicated on graphs. Vehicles were either water or BSA in water. 
Data are mean±SEM. Numerical values and statistics can be found in Table 1. 
         
Haematology values were not affected among the treatment groups (Table 2). Regarding 
plasma and urine biochemical parameters, only plasma creatinine was decreased in the 
SeNP mid-dose female group while creatinine excretion and clearance were increased for 
high-SeNP dosed male rats. Urine analysis revealed an increase in pH in urine collected 
from the selenite mid-dose female group and from the SeNP high-dose male rats. No 
effects were found in the brain concentration of any of the investigated neurotransmitters, 
dopamine, noradrenaline or 5-HT (Table 3). 
           Absolute liver weight was decreased in SeNP low-dose females and increased in 
selenite mid-dose females (Table 4). Relative liver weight was increased in both SeNP 
high-dose males and SeNP mid-dose females as well as in selenite mid-dose females 
(Table 5). In SeNP high dose males absolute testes weight as well as absolute and relative 
weights of the epididymis were decreased (Tables 4 and 5).  
       Histological examination of the livers from females exposed to low- and mid-doses 
of either SeNP or selenite and of males from SeNP high-dose group did not reveal any 
changes as compared to the respective controls. 
 
Discussion 
We aimed at assessing the toxic potential of SeNP and whether the toxicity of this 
formulation differed from that of the dissolved Se-containing molecule, selenite. Overt 
toxicity occurred at the highest dose. Body weight gain changes, changes in liver weight 
as well as some biochemical endpoints occurred at mid and low doses. Based on a 
decrease in body weight gain our data suggested that the lowest SeNP dose (0.05 mg 
Se/kg bw) was a lowest observed adverse effect level (LOAEL). This suggested that the 
no observed adverse effect level (NOAEL) for SeNP was even lower. With respect to 
literature data the toxicity of selenite and of SeNP (100-500 nm) was investigated in mice 
at doses of 0.004, 0.04 and 0.4 mg Se/kg bw. Equal toxicity was observed as both forms 
induced higher relative heart weight at lowest dose and decreased the number of white 
blood cell counts at the two lowest doses (Benko et al. 2012). Jia et al. administered SeNP 
or selenite to rats at 0.14 to 0.48 mg Se/kg bw/day, and based on haematology results and 
organ weight changes, identified a NOAEL of 0.22 mg Se/kg bw/day and 0.14 mg Se/kg 
bw/day for SeNP and selenite, respectively (Jia et al. 2005). Kojouri et al. found effects 
on serum iron, transferrin expression and increased neutrophil chemotactic activities in 
sheep at 1 mg Se/kg bw/day of SeNP dosed for 10 days (Kojouri et al. 2012a; Kojouri et 
al. 2012b). Thus, based on previously published studies on the toxicity of Se, a LOAEL 
of both SeNP and selenite could be set as low as 0.004 mg Se/kg bw/day given that 
increased relative heart weight and lowered white blood cells are considered as adverse 
effects (Benko et al. 2012). In our study we found a LOAEL of 0.05 mg Se/kg bw/day, 
which was based on reduction in body weight gain. This LOAEL was about a factor of 
10 higher than that reported by Kojouri et al. and could possibly be ascribed to 
interspecies differences, differences in formulation of SeNP and in sensitivities of end-
points used in the two studies.  
             Selenite was included to compare the nanoparticle formulation with that of 
selenite, a commonly used Se species in food supplements. Selenite decreased body 
weight gain only in animals that received the mid-dose of this Se preparation. At this dose 
the relative liver weight was also increased as observed also for SeNP. An increase in 
urinary pH at the mid-dose was a finding not seen for rats dosed with SeNP. Altogether 
these data suggest a NOAEL of 0.05 mg Se/kg bw for selenite. We note that this dose is 
1.5 fold the human tolerable upper intake level of Se when converted by difference in 
body surface area; And 10 fold the recommended human high level when considered per 
body weight. And thus, based on our data, the tolerable upper intake levels could be 
considered to be too high, as assessment factors of at least 100 would be needed to 
calculate an acceptable daily intake based on a NOAEL in mg/kg bw.  
      When comparing the two Se formulations both had effects on body weight gain and 
relative liver weight, suggesting that they targeted the same endpoints. This is in line with 
the previously published bio-distribution study of Se in the investigated animals, which 
demonstrated equal distribution to organs of Se following dosage with SeNPs or selenite 
(Loeschner et al. 2014). More specifically, for Se-containing metabolites in urine, the oral 
exposure to SeNPs or selenite led to excretion of the same Se-containing metabolites, 
namely seleno-sugars. This suggested that both forms were metabolised and excreted 
similarly (Loeschner et al. 2014). Moreover, in a previous study based on the same animal 
experiment we found that both Se formulations displayed similar effects on the general 
urine metabolome as indicated by partial least squares discriminant analyses, with 
specific differences in such putative identified metabolites as decanedioic acid and 
hydroxydecanedioic acid (Hadrup et al. 2016). Data from other studies show that ionic 
forms of Se exert toxicity at lower doses as compared to SeNPs (Zhang et al. 2001, 2005, 
2008, Jia et al. 2005, Wang et al. 2007), or that equal or almost equal effects occur 
following dosage of the two formulations (Benko et al. 2012, Kojouri, Jahanabadi, et al. 
2012, Kojouri, Sadeghian, et al. 2012). Combined with results from our study, the 
available data did not lead to any firm conclusion on whether SeNPs are less or more 
toxic as compared to dissolved Na selenite, i.e. a specific effect derived from the 
nanoparticulate form of Se cannot be substantiated. 
       We note that results from our study and from published results showed that the same 
toxicity endpoints are affected by both SeNPs and dissolved ionic Se species (Zhang et 
al. 2001, 2005, 2008, Jia et al. 2005, Wang et al. 2007, Benko et al. 2012, Kojouri, 
Sadeghian, et al. 2012, Hadrup et al. 2016). An explanation for this could be that SeNP 
are dissolved in the mammalian body to exert an effect similar to that observed for 
dissolved selenite.  
        In conclusion, SeNP and the ionised selenite at the same Se dose administered orally 
exerted effects on body weight gain and on liver weight in rats. Based on these endpoints, 
however, the low dose of 0.05 mg Se/kg bw was considered as a LOAEL for SeNP and 
as a NOAEL for selenite. Overall SeNPs and selenite exerted similar toxicity with respect 
to endpoints and dose, suggesting that a nanoparticle-specific toxicity did not occur.  
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Table 1. Body weight, water and feed intake in rats treated orally by gavage for 28 days with SeNP or selenite 
    Females           Males 
    Vehicle-BSA SeNP  SeNP  Vehicle-H2O Selenite Selenite  Vehicle-BSA SeNP 
      low-dose mid-dose   low-dose mid-dose   high-dose 
Dose (mg/kg bw/day)   0 (n=8)  0.05 (n=6) 0.5 (n=6) 0 (n=8)  0.05 (n=8) 0.5 (n=8) 0 (n=6)  4 (n=4 at 
end) 
 
Body wt. start (g)   134±8  125±8   126±13  133±8  131±5  132±10  171±12  176±7 
Body wt. end (g)  188±12  166±9*  170±22  180±11  177±5  175±10  285±14  249±16†† 
Body wt. gain (g)  54±9  41±5*** 45±11** 47±7  46±7  44±4§  114±14  74±16††† 
Feed intake (g/animal/day) 15±0.3  13±1  14±1  15±0.4  14±0.4  15±1  17±4  17±2 
Relative feed intake  83±2  79±3  81±5  84±6  81±2  83±3  60±11  69±9 
(g/kg bw/day) 
Water intake   24±2  20±1  23±3  22±1  22±5  17±2  33±4  27±1 
(mL/animal/day) 
Relative water intake  128±8  124±6  133±22  123±11  121±29  97±14  115±8  111±4 
(mL/kg bw/day) 
 
Body weight gain was analysed by one-way-ANOVA taking all time points into consideration. *indicates significance by one-way ANOVA followed by 







Table 2. Hematology in rats treated orally by gavage for 28 days with SeNP or selenite 
   Females           Males 
   Vehicle-BSA SeNP  SeNP  Vehicle-H2O Selenite Selenite  Vehicle-BSA SeNP  
     low-dose mid-dose   low-dose mid-dose   high-dose  
Dose (mg/kg bw/day) 0 (n=8)  0.05 (n=6) 0.5 (n=6) 0 (n=8)  0.05 (n=8) 0.5 (n=8) 0 (n=6)  4 (n=4 at end) 
 
WBC (10(9)/l ) 3.8±1.4  4.4±1.9  4.4±1.3  5.2±1.1  5.0±1.4  5.2±2.0  4.8±1.1  5.9±1.5 
L (%)   85±5    84±7    83±8    84±4  85±5 
M (%)   2.3±0.8    2.5±2.4    3.1±1.7    2.5±1.3  2.1±0.5 
N (%)   12±5    12±5    13±6    13±4  13±5 
E (%)   0.5±0.4    1.3±1.2    1.3±1.3    0.7±0.3  0.6±0.6 
B (%)   0.3±0.6    0.1±0.3    0.3±0.5    0.3±0.5  0.0±0.0 
RBC (10(12)/L) 7.5±0.3  7.7±0.5  7.6±0.4  7.8±0.6  7.7±0.3  7.5±0.5  8.1±0.4  8.0±0.5 
HGB (mM)  9.3±0.2  9.6±0.3  9.4±0.5  9.5±0.5  9.4±0.3  9.3±0.4  9.7±0.5  9.2±0.5 
HCT (%)  42.2±0.9 43.0±2.6 42.3±2.7 43.2±2.4 42.7±1.4 42.0±2.3 44.7±2.1 43.2±2.9 
PLT (10(9)/l)  824±93  664±147 683±132 771±57  780±121 738±83  682±85  661±245 
MPV (fL)  6.1±0.1  6.1±0.2  6.0±0.1  6.1±0.2  6.1±0.2  6.1±0.2  6.4±0.2  6.2±0.4 
RDW (%)  12.2±0.6 11.7±0.8 11.9±0.2 11.8±0.3 11.9±0.3 12.3±0.4 12.7±0.6 13.3±0.4 
MCV (fL)  56.0±1.2 55.8±0.8 56.0±1.3 55.8±1.5 55.5±0.8 56.3±1.3 55.5±1.9 54.3±2.5 
MCH (fmol)  19.8±0.7 19.9±0.9 19.9±0.9 19.7±0.8 19.6±0.4 19.9±1.0 19.2±0.8 18.4±0.6 
MCHC (mM)  35.3±1.0 35.6±1.3 35.6±1.3 35.3±0.8 35.4±0.7 35.5±1.1 34.6±0.6 34.0±0.5 
 
WBC: White blood cells, RBC: erythrocytes, HGB: haemoglobin concentration, RDW: Red cell distribution width,  MPV: Mean platelet volume, Hct: 
haematocrit, PLT: Platelets, MCV: Mean corpuscular volume, MCH: Mean corpuscular haemoglobin, MCHC: Mean corpuscular haemoglobin Concentration, 
L: Lymphocytes, M: Monocytes, N: Neutrophil granulocytes, E: Eosinophil granulocytes, B: Basophil granulocytes. For leukocyte distribution 100 cells from 
each animal were counted. Data are mean ± SD. There were no statistically significant differences. 
 
 
Table 3. Clinical biochemical and brain neurotransmitter levels in rats treated orally by gavage for 28 days with SeNP or selenite 
    Females           Males 
    Vehicle-BSA SeNP  SeNP  Vehicle-H2O Selenite Selenite  Vehicle-BSA SeNP 
      low-dose mid-dose   low-dose mid-dose   high-dose 
Dose (mg/kg bw/day)   0 (n=8)  0.05 (n=6) 0.5 (n=6) 0 (n=8)  0.05 (n=8) 0.5 (n=8) 0 (n=6)  4 (n=4 at 
end) 
 
ALT (u/L)    53±14  47±17  55±18  53±21       60±22  62±16  69±8  90±23  
Cholesterol (mM)  1.8±0.5  1.5±0.4  1.8±0.4  1.4±0.3       1.6±0.1  1.8±0.7  1.8±0.2  2.2±0.5 
Protein (g/L)   66±7  66±2  63±2  69±5       70±1  67±2  63±2  65±3 
ALP (u/L)   291±97  257±44  242±86  243±88       259±68  235±73  423±130 665±427 
Glucose (mM)   6.2±1.5  6.7±1.6  6.1±1.0  6.2±1.6       6.9±0.9  6.4±0.8  7.6±1.7  8.9±1.6 
Urea (mM)   21±3  22±4  20±2  20±3       19±4  20±2  20±3  21±4 
Plasma creatinine (µM)  36±6  32±2  30±3*  32±3       32±2  30±2  27±3  30±4 
Twentyfour hour urine   
volume (mL/100 g bw)  49±12  56±16  56±20  66±38  59±19  40±20  28±16  32±5 
Urine creatinine (µM)  2859±907 2980±1248 3108±2000 2370±760 2276±841 3408±1605 2752±1045 3129±387 
Creatinine excretion  
(µmol/100 g bw/day)  133±26  154±37  146±86  139±90  122±24  113±17  64±7  100±16### 
Creatinine clearance  3784±865 4818±1073 4823±1813 4281±1546 3206±130 3776±530 2376±288 3430±965# 
 (mL/100 g bw/day) 
Urine pH   6.2±0.6  6.1±0.2  6.5±0.4  6.3±0.5  6.2±0.2  6.9±0.6* 6.5±0.3  7.4±0.5¤ 
Brain dopamine   15.2±2.2 15.2±1.6 13.6±4.0 16.0±3.7 16.1±1.2 16.7±1.5 19.2±1.7 20.2±0.4 
(nmol/ g brain tissue) 
Brain noradrenaline  5.6±1.4  6.9±0.7  7.3±3.6  6.4±1.6  6.2±0.8  6.1±0.6  6.4±0.7  7.2±0.8 
(nmol/ g brain tissue) 
Brain 5-HT   1.7±0.2  1.7±0.1  1.7±0.5  1.8±0.2  1.8±0.2  1.9±0.1  1.7±0.1  1.8±0.02 
(nmol/ g brain tissue) 
ALT: alanine aminotransferase, ALP: alkaline phosphatase. N is 6-8. Data are mean ± SD. *designates p<0.05 by Dunn’s multiple comparisons test (Kruskal-
Wallis) vs. Control,  ¤designates p<0.05 by Mann-Whitney test vs. Male vehicle-BSA .###designates p<0.001 by students t-test vs. Male vehicle-BSA .#designates 
p<0.005 by students t-test vs. Male vehicle-BSA.  
Table 4. Absolute organ weights of rats treated orally by gavage for 28 days with SeNP or selenite 
   Females           Males 
   Vehicle-BSA SeNP  SeNP  Vehicle-H2O Selenite Selenite  Vehicle-BSA SeNP 
     low-dose mid-dose   low-dose mid-dose   high-dose 
Dose (mg/kg bw/day)  0 (n=8)  0.05 (n=6) 0.5 (n=6) 0 (n=8)  0.05 (n=8) 0.5 (n=8) 0 (n=6)  4 (n=4 at end) 
 
Adrenals (g)  0.06±0.01 0.06±0.01 0.06±0.01 0.06±0.01 0.06±0.01 0.06±0.02 0.06±0.01  0.05±0.00 
Brain (g)  1.75±0.05 1.68±0.07 1.70±0.08 1.73±0.08 1.73±0.07 1.67±0.08 1.96±0.07 1.85±0.03 
Heart (g)  0.64±0.05 0.62±0.03 0.60±0.04 0.61±0.02 0.64±0.06 0.64±0.05 0.92±0.08 0.90±0.16 
Kidneys (g)  1.35±0.11 1.24±0.07 1.28±0.10 1.29±0.10 1.31±0.13 1.33±0.13 1.90±0.10 1.86±0.12 
Liver (g)  5.40±0.30 4.63±0.20* 5.67±0.75 4.97±0.44 4.91±0.48 6.09±0.50§§§ 7.61±0.59 9.33±0.88 
Lnd. Mesenteric (g) 0.18±0.03 0.18±0.03 0.16±0.05 0.21±0.05 0.20±0.07 0.21±0.04 0.32±0.06 0.27±0.07 
Ovaries (g)  0.09±0.01 0.08±0.01 0.09±0.02 0.09±0.01 0.10±0.01 0.09±0.01 
Spleen (g)  0.47±0.06 0.39±0.03* 0.44±0.07 0.43±0.05 0.44±0.04 0.48±0.05 0.64±0.09 0.66±0.13 
Testes (g)              3.27±0.39 2.63±0.28† 
Epididymis (g)              0.75±0.04 0.57±0.10†† 
Thymus (g)  0.47±0.12 0.39±0.06 0.40±0.07 0.44±0.10 0.45±0.04 0.37±0.05 0.48±0.09 0.34±0.05 
N is 4-8. One-way ANOVA with Dunnet’s post-test was conducted on female SeNP groups and vehicle. Student’s t-test was conducted compare male SeNP 
with vehicle. Data are mean ± SD. *indicates significance by one-way ANOVA followed by Dunnet’s post-test, vehicle vs. SeNP 0.05 and SeNP 0.5 mg/kg 
bw/day in the female group. § indicates significance by one-way ANOVA followed by Dunnet’s post-test, vehicle vs. selenite 0.05, and selenite 0.5 mg Se/kg 
bw/day. † indicates significance by t-test vs. male vehicle. Lnd. is an abbreviation for lymph node. For testes and kidneys the reported weights are combined 
weights of both the right and left organs. 
 
  
Table 5. Relative organ weights of rats treated orally by gavage for 28 days with SeNP or Selenite 
   Females           Males 
   Vehicle-BSA SeNP  SeNP  Vehicle-H2O Selenite Selenite  Vehicle-BSA SeNP 
     low-dose mid-dose   low-dose mid-dose   high-dose 
Dose (mg/kg bw/day)  0 (n=8) 0.05 (n=6) 0.5 (n=6) 0 (n=8)  0.05 (n=8) 0.5 (n=8) 0 (n=6)  4 (n=4 at end) 
(g/100 g bw)  
Adrenals   0.03±0.01 0.04±0.01 0.04±0.00 0.04±0.01 0.03±0.00 0.03±0.01 0.02±0.00 0.02±0.00 
Brain    0.93±0.05 1.02±0.07 1.00±0.10 0.96±0.05 0.98±0.05 0.96±0.06 0.69±0.05 0.75±0.04 
Heart     0.34±0.04 0.37±0.02 0.35±0.02 0.34±0.02 0.36±0.03 0.36±0.03 0.32±0.02 0.36±0.07 
Kidney   0.72±0.04 0.75±0.04 0.76±0.04 0.72±0.06 0.74±0.05 0.76±0.04 0.67±0.04 0.75±0.06 
Liver    2.88±0.13 2.81±0.21 3.34±0.26** 2.76±0.21 2.78±0.25 3.48±0.22§§§ 2.67±0.11 3.77±0.21††† 
Lnd. Mesenteric 0.10±0.02 0.11±0.02 0.10±0.02 0.11±0.02 0.12±0.04 0.12±0.03 0.11±0.02 0.11±0.03 
Ovaries   0.05±0.01 0.05±0.01 0.05±0.01 0.05±0.00 0.05±0.01 0.05±0.01 
Spleen   0.25±0.02 0.24±0.02 0.26±0.04 0.24±0.03 0.25±0.03 0.28±0.03§ 0.22±0.03 0.27±0.05 
Testes               1.15±0.10 1.06±0.04 
Epididymis              0.26±0.02 0.23±0.03† 
Thymus  0.25±0.06 0.23±0.03 0.24±0.02 0.24±0.04 0.25±0.02 0.21±0.03 0.17±0.03 0.14±0.01 
N is 4-8. One-way ANOVA with Dunnet’s post-test was conducted on female SeNP groups and vehicle. Student’s t-test was conducted compare male SeNP 
with vehicle. Data are mean ± SD. *indicates significance by one-way ANOVA followed by Dunnet’s post-test, vehiclevs. SeNP 0.05 and SeNP 0.5 mg/kg 
bw/day in the female group. § indicates significance by one-way ANOVA followed by Dunnet’s post-test, vehicle vs. selenite 0.05 and selenite 0.5 mg Se/kg 
bw/day. † indicates significance by t-test vs. male vehicle. Lnd. is an abbreviation for lymph node. For testes and kidneys the reported weights are combined 
weights of both the right and left organs. 
 
